Radioimmunotherapy for B-cell non-Hodgkin lymphoma
Author:
Publisher
Elsevier BV
Subject
Clinical Biochemistry,Oncology
Reference59 articles.
1. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program;McLaughlin;Journal of Clinical Oncology,1998
2. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group;Witzig;Journal of Clinical Oncology,2005
3. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation;Colombat;Blood,2001
4. Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma: results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B;Hochster;Blood,2005
5. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma;Marcus;Blood,2005
Cited by 34 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Preclinical study of 212Pb alpha-radioimmunotherapy targeting CD20 in non-Hodgkin lymphoma;British Journal of Cancer;2021-10-20
2. Biomarker detection of Parkinson’s disease: therapy and treatment using nanomaterials;Nanomaterials in Diagnostic Tools and Devices;2020
3. 212Pb α-Radioimmunotherapy Targeting CD38 in Multiple Myeloma: A Preclinical Study;Journal of Nuclear Medicine;2019-12-20
4. PLASMID DESIGN FOR PRODUCTION OF CHIMERIC ANTIBODIES WITH DEFINED SPECIFICITY IN EUKARYOTES;Journal of microbiology epidemiology immunobiology;2017-12-28
5. Impact of PET and MRI threshold-based tumor volume segmentation on patient-specific targeted radionuclide therapy dosimetry using CLR1404;Physics in Medicine & Biology;2017-07-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3